Doctor Care Anywhere has announced its acquisition of Outcome Diagnostics Limited and Medic Spot Limited for £850,000, with the aim of expanding GLP-1 capabilities and cross-selling opportunities in. the UK market.
According to Doctor Care Anywhere, the acquisition marks an “important step” in the company’s growth plan, offering an immediate presence in the UK weight management industry and a platform for direct-to-consumer services to be expanded in the region.
Pointing especially to the performance of Outcome Diagnostics Limited’s 11-person team in delivering strong results in the weight management market, Doctor Care Anywhere states it is “pleased to welcome this high–performing team and the proven direct–to–consumer (“D2C”) capability they bring”.
Plans are to use these new expanded capabilities to accelerate Doctor Care Anywhere’s offering around virtual GP, mental health, physiotherapy, and assessment products, it adds, with the intention to cross-sell services to the business’s existing clients.
Laura O’Riordan, Doctor Care Anywhere’s CEO, said: “I am delighted to welcome the Medicspot team to Doctor Care Anywhere! Both teams are excited by the opportunity to grow faster by collaborating. I know we will focus intently over the coming months on integrating the teams and delivering customer growth we believe can follow from strong execution.”
Wider trend: Acquisitions, funding, and investments from across the health sector
Liverpool-based Spotlight Pathology has secured £1.4 million in seed funding to support the development of its AI-powered blood cancer diagnostics software. The funding round was co-led by the UK Innovation and Science Seed Fund (UKI2S) and Liverpool City Region Seed Fund. Funding will be used toward product development, regulation, and clinical adoption for the company’s AI software capable of analysing digital pathology images to support the earlier identification of blood cancers.
NHS England has awarded a contract with a value of up to £160 million to IBM as a strategic delivery partner for the future of the NHS App. “Following the completion of a competitive procurement process and due governance, IBM has been formally appointed as a strategic delivery partner as we continue to develop secure, reliable and user-centred pathways and services at scale,” NHSE states. The contract is due to begin on 1 May 2026, ending on 31 March 2028.
European AI and digital health company Doctolib, has announced an investment into Medicus with commitments of over £100 million, to hire 150 people and establish a full R&D centre in London. “Doctolib and Medicus will build on the strong product, team and understanding of NHS primary care that Medicus has built, while bringing Doctolib’s AI and technological expertise and track record with more than 40,000 GPs in Europe,” it states.
